217 related articles for article (PubMed ID: 7475600)
1. Sex mismatch as a risk factor for chronic rejection of liver allografts.
Candinas D; Gunson BK; Nightingale P; Hubscher S; McMaster P; Neuberger JM
Lancet; 1995 Oct; 346(8983):1117-21. PubMed ID: 7475600
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for chronic rejection after pediatric liver transplantation.
Gupta P; Hart J; Cronin D; Kelly S; Millis JM; Brady L
Transplantation; 2001 Sep; 72(6):1098-102. PubMed ID: 11579307
[TBL] [Abstract][Full Text] [Related]
3. An association between cytomegalovirus infection and chronic rejection after liver transplantation.
Evans PC; Soin A; Wreghitt TG; Taylor CJ; Wight DG; Alexander GJ
Transplantation; 2000 Jan; 69(1):30-5. PubMed ID: 10653376
[TBL] [Abstract][Full Text] [Related]
4. Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure.
Dogan N; Hüsing-Kabar A; Schmidt HH; Cicinnati VR; Beckebaum S; Kabar I
J Int Med Res; 2018 Sep; 46(9):3979-3990. PubMed ID: 29996675
[TBL] [Abstract][Full Text] [Related]
5. The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis.
Patel YA; Henson JB; Wilder JM; Zheng J; Chow SC; Berg CL; Knechtle SJ; Muir AJ
Clin Transplant; 2018 Oct; 32(10):e13388. PubMed ID: 30136315
[TBL] [Abstract][Full Text] [Related]
6. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
7. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation.
Mañez R; White LT; Linden P; Kusne S; Martin M; Kramer D; Demetris AJ; Van Thiel DH; Starzl TE; Duquesnoy RJ
Transplantation; 1993 May; 55(5):1067-71. PubMed ID: 8388584
[TBL] [Abstract][Full Text] [Related]
8. Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts.
Evans PC; Smith S; Hirschfield G; Rigopoulou E; Wreghitt TG; Wight DG; Taylor CJ; Alexander GJ
J Hepatol; 2001 May; 34(5):711-5. PubMed ID: 11434617
[TBL] [Abstract][Full Text] [Related]
9. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients.
Herzog D; Soglio DB; Fournet JC; Martin S; Marleau D; Alvarez F
Liver Transpl; 2008 Jul; 14(7):946-55. PubMed ID: 18581476
[TBL] [Abstract][Full Text] [Related]
10. Chronic rejection of the liver allograft.
Lowes JR; Hubscher SG; Neuberger JM
Gastroenterol Clin North Am; 1993 Jun; 22(2):401-20. PubMed ID: 8389736
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation.
O'Grady JG; Alexander GJ; Sutherland S; Donaldson PT; Harvey F; Portmann B; Calne RY; Williams R
Lancet; 1988 Aug; 2(8606):302-5. PubMed ID: 2899720
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors of chronic rejection in kidney transplantation, results of a single center study].
Delmas S; Picot MC; Vergnes C; Cristol JP; Mourad G
Nephrologie; 1999; 20(3):153-8. PubMed ID: 10418005
[TBL] [Abstract][Full Text] [Related]
13. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection.
Wiesner RH; Batts KP; Krom RA
Liver Transpl Surg; 1999 Sep; 5(5):388-400. PubMed ID: 10477840
[TBL] [Abstract][Full Text] [Related]
14. The effect of donor gender on graft survival.
Zeier M; Döhler B; Opelz G; Ritz E
J Am Soc Nephrol; 2002 Oct; 13(10):2570-6. PubMed ID: 12239247
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary Cirrhosis: A Japanese Multicenter Study.
Egawa H; Sakisaka S; Teramukai S; Sakabayashi S; Yamamoto M; Umeshita K; Uemoto S
Am J Transplant; 2016 Apr; 16(4):1248-57. PubMed ID: 26731039
[TBL] [Abstract][Full Text] [Related]
16. Increased bile duct complications in liver transplantation across the ABO barrier.
Sanchez-Urdazpal L; Batts KP; Gores GJ; Moore SB; Sterioff S; Wiesner RH; Krom RA
Ann Surg; 1993 Aug; 218(2):152-8. PubMed ID: 8342994
[TBL] [Abstract][Full Text] [Related]
17. Retransplant as Rescue Treatment for ABO-Compatible Living-Donor Liver Transplant Related Antibody-Mediated Rejection: A Case Report.
Ho MH; Wu SY; Ou KW; Su TF; Hsieh CB
Exp Clin Transplant; 2018 Apr; 16(2):222-226. PubMed ID: 26742858
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation.
Hoffmann RM; Günther C; Diepolder HM; Zachoval R; Eissner HJ; Forst H; Anthuber M; Paumgartner G; Pape GR
Transpl Int; 1995; 8(5):353-9. PubMed ID: 7576016
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen and adult living-donor liver transplantation outcomes: an analysis of the organ procurement and transplantation network database.
Jakab SS; Navarro VJ; Colombe BW; Daskalakis C; Herrine SK; Rossi S
Liver Transpl; 2007 Oct; 13(10):1405-13. PubMed ID: 17902126
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
